[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600139":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":30,"responsibleParty":46,"collaborators":20,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":20,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Sohag University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"this group will receive Eltrombopag tabelts","EXPERIMENTAL","ITP patients in this group receive Eltrombopag then follow up by liver functions test to evulate occurance of liver disorders .",[13],"Drug: Eltrombopag",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Eltrombopag","ITP patients will receive Eltrombopag and evulate occurance of liver disordres .",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Peter A Alfy, Resident","CONTACT","01274069691","peter.adel.dola@gmail.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":20},"Usama M Abdelaal, Professor","01065962094",[31],{"facility":32,"status":33,"city":34,"state":20,"zip":20,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Sohag university hospital","RECRUITING","Sohag","Egypt","EG",{"type":38,"coordinates":39},"Point",[40,41],31.69478,26.55695,{"lat":41,"lon":40},[44],{"name":45,"role":24,"phone":20,"phoneExt":20,"email":20},"Magdy M Amin, Professor",{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Peter Adel Alfy","Resident , Internal medicine, Faculty of Medicine Sohag university","100600139","eltrombopag-induced-liver-dysfunction-during-treatment-of-immunethrombocytopenic-purpura-100600139",false,"NCT07093606","Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura","Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver\n\nExclusion Criteria:\n\nPre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.","ALL","18 Years","75 Years",{"count":60,"type":61},100,"ESTIMATED","INTERVENTIONAL",[64],"NA","this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.",[67],"ITP - Immune Thrombocytopenia","2025-07-23",{"date":70,"type":71},"2025-07-30","ACTUAL",{"date":73,"type":71},"2025-07-14",{"date":75,"type":61},"2026-01-20",{"name":5,"class":6},1]